Brought to you by 
Dance Biopharm raises $9.5mm through sale of convertible debt and warrants
19 Feb 2015
Executive Summary
Dance Biopharm Inc. (inhaled insulin for diabetes) raised $9.5mm through the sale of convertible notes and warrants to a syndicate of institutional investors and individuals. SternAegis Ventures (through Aegis Capital) was the placement agent. Funds will support ongoing late-stage trials of its Dance501 pocket-sized inhaler device.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- Convertible Debt
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Dance Biopharm raises $9.5mm through sale of convertible debt and warrants
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice